Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)

Clinical trial NCT07362238 · RECRUITING

Trial details

NCT number: NCT07362238
Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Immune Thrombocytopenia Treatment

Start date: 2026-03-01
Primary completion: 2028-03-01
Enrollment: 122

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.